Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.78 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | EED | O75530 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.63 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.63 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357504 | 1.00 | EZH2 (0.78) | EZH2EZH1NR1I2EEDABCB11 | |
| SCHEMBL19391445 | 0.94 | EZH2 (0.69) | EZH2EZH1 | |
| SCHEMBL16517927 | 0.94 | EZH2 (0.68) | EZH2EZH1 | |
| SCHEMBL12684073 | 0.93 | EZH2 (0.67) | EZH2EZH1 | |
| SCHEMBL12498927 | 0.92 | EZH2 (0.67) | EZH2EZH1 | |
| SCHEMBL12499081 | 0.92 | EZH2 (0.66) | EZH2EZH1 | |
| SCHEMBL12684373 | 0.91 | EZH2 (0.64) | EZH2EZH1 | |
| SCHEMBL12684409 | 0.91 | EZH2 (0.66) | EZH2EZH1 | |
| SCHEMBL12684040 | 0.91 | EZH2 (0.71) | EZH2EZH1 | |
| SCHEMBL12684479 | 0.91 | EZH2 (0.65) | EZH2EZH1NR1I2EEDABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | claimed |
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| WO-2023056236-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20210213013-A1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FONDATION ASILE DES AVEUGLES (CH) | 2021-07-15 | — | — | US | claimed |
| US-20210128600-A1 | Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2021-05-06 | — | — | US | claimed |
| WO-2017192290-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC DRUGS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-11-09 | — | — | WO | claimed |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | The Wistar Institut of Anatomy and Biology (US) | 2024-07-16 | — | — | US | disclosed |
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | disclosed |
| CN-117979962-A | Novel synergistic combinations for treating cancer and methods of use thereof | 波尔多大学 | 2024-05-03 | — | — | CN | disclosed |
| US-20240024331-A1 | METHOD FOR TREATING CANCER | Epizyme, Inc. | 2024-01-25 | — | — | US | disclosed |
| US-20240024331-A1 | METHOD FOR TREATING CANCER | Epizyme, Inc. | 2024-01-25 | — | — | US | disclosed |
| EP-4309738-A2 | METHOD OF TREATING MEDULLOBLASTOMA WITH AN EZH2 INHIBITOR | Epizyme Inc (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2013138361-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2013-02-14 | — | — | US | disclosed |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2013-02-14 | — | — | US | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH2 1/4885EZH1 2/4885NR1I2 701/4885 |
| US-20240024331-A1 | METHOD FOR TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885EZH1 4/4885NR1I2 3146/4885 |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EZH1 2661/4885NR1I2 657/4885 |
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | EZH2, DOT1L, PRDM7 | EZH2 1/4885EZH1 10/4885NR1I2 2379/4885 |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | CARM1, EZH2, PRMT1 | EZH2 2/4885EZH1 31/4885NR1I2 1955/4885 |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | EZH2 1/4885EZH1 10/4885NR1I2 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.